TopoTarget increases share capital
Danish drugmaker TopoTarget AS has decided to increase its issued share capital by up to a nominal amount of 4,153,170 Danish kroner represented by up to 4,153,170 ordinary shares with a nominal value of 1 kroner each, by means of a directed issue to a number of Danish and foreign institutional investors, including specialized European biotechnology funds.
The new shares will be placed by ABN AMRO Rothschild and Handelsbanken Capital Markets after consultation with the company's board of directors. The nominal amount of TopoTarget's issued share capital is, prior to the capital increase, 41,531,710 represented by 41,531,710 ordinary shares with a nominal value of 1 kroner each.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze